Sofinnova Partners

We are proud to share that we have been featured in Sofinnova Partners’ 2024 ESG Report as one of the firms demonstrating the strongest year-over-year ESG progress, representing the digital medicine category. For an industry where trust drives every decision, this recognition reinforces that the future of clinical AI depends on the strength of the infrastructure behind it.   Healthcare organisations are looking for partners who can scale responsibly and stay accountable as they grow. deepc’s ESG progress reflects that mindset. Stronger governance and a long-range climate strategy. The company’s first complete carbon footprint baseline. These steps reinforce the backbone that supports deepcOS® and help healthcare leaders understand exactly what stands behind the technology they adopt.   Sustainability shapes daily choices across the company. It guides how suppliers are evaluated, how events are planned and how teams think about the impact of the systems they build. The direction is clear. Healthcare AI earns trust when its infrastructure is built with the same care as its performance.   Read the full announcement now: https://lnkd.in/dJsNG7h6

Last week, Sofinnova Partners and LifeSci Capital LLC kicked off Jefferies Week in London with our annual Growth & Innovation Summit, an invite-only forum connecting leading investors with the innovators shaping what’s next in life sciences. Through high-value meetings, candid conversations about investor appetite, IPO readiness, and the return of biotech M&A, the summit offered a clear snapshot of where the industry is heading. Thank you to everyone who joined us. We look forward to continuing to host this summit and creating meaningful opportunities for connection across the global life sciences ecosystem.

Congratulations to the AFYREN team on today’s milestone: a €23M share capital increase to optimize and expand the AFYREN NEOXY biorefinery.   Why this matters: • Industrial-scale validation of bio‑based chemistry—moving from promise to production at real capacity • Europe builds strategic manufacturing for low‑carbon ingredients, strengthening supply security across key sectors • Momentum to bring new derivatives to market and expand into new geographies • A milestone in a long journey we’ve supported from the start—Sofinnova invested in 2019 and has backed AFYREN’s scale‑up ever since   Bravo to Nicolas Sordet and the AFYREN team. We’re proud to support your mission and momentum 👏.

Celebrating Innovation 💡 and Partnership 🤝 At Moon Surgical, we believe that the future of surgery lies at the intersection of robotics, AI, and human expertise. True Physical AI at the surgeon's fingertips for greater OR efficiency in high volume, low acuity settings. Our collaboration with NVIDIA, one of our key investors and a close R&D partner, is helping us make that vision a reality. We’re proud to see this partnership highlighted in https://lnkd.in/eHRBC95r. Together, we’re leveraging cutting-edge AI technologies to empower surgical teams, improve patient experience, and address critical challenges in healthcare accessibility and cost management. A special thank you to Kimberly Powell and the incredible NVIDIA team for their trust and support. Your commitment to advancing healthcare through technology inspires us every day. The journey to transform surgery is just beginning—and we’re excited to shape it together. #AI #PhysicalAI #Robotics #HealthcareInnovation #Partnership #MoonSurgical #NVIDIA Jeffery Alvarez David Noonan Mohamed (Sid) Siddeek Antoine Papiernik Frederic Moll Jonathan C. Eric Ermenault Jeff Driggs Sofinnova Partners MD Start

The close of Sofinnova Partners’ €650 million early-stage biotech fund isn’t just about numbers — it’s about what this enables: advancing breakthrough science, supporting visionary founders, and ultimately improving patient lives. From Axios and BioCentury Inc. to Les Echos, L'AGEFI, Il Sole 24 Ore, MedWatch, Private Equity Magazine, CFNEWS, and BiotechTV — each outlet highlighted a different dimension of how this fund will shape the future of healthcare innovation. 👉 Want to delve deeper? Link to the coverage in the comments.

Tune in at 19:45 CET tonight to Class CNBC Speciale for Graziano Seghezzi’s conversation with Emerick de Narda on what Sofinnova Capital XI €650M — part of over €1.5B raised for life sciences — means for the Italian ecosystem. They discuss the fragile IPO market, resilient M&A-driven exits, and Italy’s growing biotech momentum with success stories like NanoPhoria and AAVantgarde. 🔗 in comments.

Behind every great fund is a team of exceptional people. Sofinnova Capital XI reflects the experience, conviction, and vision of our Partners: Antoine Papiernik, Henrijette Richter, Graziano Seghezzi, Maina Bhaman, Karl Naegler and Anta Gkelou. Together, they are shaping the future of early-stage healthcare innovation across Europe and beyond. 🙌

𝗢𝗻 CNBC’𝘀 𝗦𝗾𝘂𝗮𝘄𝗸 𝗕𝗼𝘅 𝗘𝘂𝗿𝗼𝗽𝗲 𝘁𝗵𝗶𝘀 𝗺𝗼𝗿𝗻𝗶𝗻𝗴, Antoine Papiernik spoke with Stephen Sedgwick, Karen Tso, and Julianna Tatelbaum about Sofinnova Partners €650M raise for Sofinnova Capital XI as part of the firm’s €1.5B capital raised over the past 12 months   A great conversation on how we’re supporting the next generation of life sciences innovators. Watch the full interview in the link in comments

𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗶𝗻𝗴 𝗦𝗼𝗳𝗶𝗻𝗻𝗼𝘃𝗮 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 𝗫𝗜: €𝟲𝟱𝟬𝗠 ($𝟳𝟱𝟬𝗠). 🚀🚀🚀  Our largest fund to date—above target—and part of €1.5B raised across Sofinnova in the past 12 months. This enables us to support 50–60 new companies and power the next wave of biotech & medtech innovation. The mandate is clear: back exceptional early‑stage founders across Europe & North America and turn breakthrough science into patient impact. Thank you to our investors and partners for your trust and continued conviction. Onward! A link to the press release in the comments.

Congratulations to Inventiva Pharma, a Sofinnova Partners portfolio company on its $150 million fundraise to advance new oral therapies for MASH (metabolic dysfunction-associated steatohepatitis). This is an exciting milestone for Inventiva as it continues to move its Phase 3 NATiV3 trial forward and bring much-needed innovation to patients living with liver disease. 👉 Learn more in the press release linked in the comments.